International Journal of Medicine and Data

Objective To explore the application effect of carboprost tromethamine injection combined with carbetocin in the prevention and treatment of postpartum hemorrhage after cesarean section. Methods A total of 80 parturients who underwent cesarean section from November 2023 to November 2024 were selected. Using the random number table method, they were respectively treated with carbetocin (control group) and carboprost tromethamine injection combined with carbetocin (study group). Results The TT (12.21 ± 0.11) s, FIB (3.65 ± 0.17) g/L, and D-D (3.71 ± 0.15) mg/L in the study group; TT (13.25 ± 0.54) s, FIB (3.13 ± 0.13) g/L, and D-D (3.50 ± 0.24) mg/L in the control group. There were significant differences in coagulation indicators, P < 0.05. In the study group, there were 2 cases (5.00%) of postpartum hemorrhage, and the postpartum 24-hour bleeding volume was (521.28 ± 71.54) mL; in the control group, there were 9 cases (22.50%) of postpartum hemorrhage, and the postpartum 24-hour bleeding volume was (570.15 ± 80.18) mL, P < 0.05. The CRP (6.61 ± 1.52) mg/L, IL-6 (19.67 ± 2.51) ng/L, and PCT (3.01 ± 1.01) μg/L in the study group; CRP (8.57 ± 1.49) mg/L, IL-6 (24.10 ± 2.87) ng/L, and PCT (4.41 ± 1.25) μg/L in the control group. There were significant differences in inflammatory stress indicators, P < 0.05. Conclusion During cesarean section, by jointly applying carboprost tromethamine injection and carbetocin for treatment, it can prevent and treat postpartum hemorrhage, which is of great significance for reducing postpartum hemorrhage volume. No serious adverse reactions occurred during the treatment period, and the safety was high. It is worthy of clinical promotion.

Carboprost tromethamine injection; Carbetocin; Cesarean section; Postpartum hemorrhage